A double-antibody enzyme-linked immunosorbent assay (ELISA) 
booster injection of the toxoid. The antibody titer stayed level until the second booster at 12 weeks. The titer then continued to rise throughout the remaining study period. The (4) . The potential importance of the toxin in biological warfare has led to vaccination of selected members of the military as well as laboratory workers. A rapid assay for evaluation of vaccination and monitoring the immune status of vaccinated individuals could be extremely important. At the present, a pentavalent (A, B, C, D, and E) botulinum toxoid distributed through the Centers for Disease Control, Atlanta, Ga., is used for vaccination of laboratory workers. The aluminum phosphate-absorbed toxoid is derived from Formalin (0.022%)-inactivated, partially purified botulinum toxins of types A, B, C, D, and E (1). The only available procedure that has been used for evaluation of botulinum vaccine (1) and determination of antibody levels in antitoxin-treated patients (3) is the mouse neutralization assay. Survival of mice protected with botulinum antitoxin and death of unprotected mice after inoculation with the toxin constitutes a positive assay. The mouse neutralization assay is generally considered cumbersome and undesirable, since it involves sacrificing large numbers of animals and requires up to 4 days to complete.
The purpose of this study was to develop a sensitive and rapid alternative procedure for measurements of antibodies to C. botulinum type A toxin and to study the kinetics of antibody response of a volunteer to the toxoid.
A double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) for the detection of C. botulinum type A antitoxin was developed by using a type A antitoxin prepared in rabbits. Details of the method of preparation and specificity testing of the antitoxin are given elsewhere (2) . Wells of U-bottomed microtiter plates were coated with 100 ,ul of a 1:5,000 dilution of the type A botulinal antitoxin. After overnight incubation at 4°C, the coated plates were washed as described previously (2) . A 100-,ul sample of a 1:40 dilution of a C. botulinum type A culture filtrate (strain I62) was added to the wells. Plates were then incubated at 37°C for 90 min, and excess toxin was removed by washing. Serum samples diluted 1:80 were then added to the appro-private wells, and plates were again incubated at 37°C for 90 min. Each serum sample was tested in triplicate in each run. In addition to test samples, positive control sera (antisera from vaccinated individuals) and negative control sera (from nonvaccinated, healthy individuals) were included in the assay. After the wells were washed, 100 ,ul of a 1:800 dilution of alkaline phosphate-conjugated goat anti-human immunoglobulin G (Miles Laboratories, Inc., Elkhart, Ind.) was added. Incubation of plates (37°C, 90 min) was followed by washing of the wells and the addition of 100 ,ul of a 1-mg/ml solution of p-nitrophenyl phosphate (Sigma 104 phosphatase (2) .
The volunteer was a 40-year-old male who received a deep subcutaneous injection of 0.5 ml of pentavalent (A, B, C, D, and E) botulinal toxoid at 0, 2, and 12 weeks, according to the instructions given by the Centers for Disease Control. Serum samples were collected 2 weeks before and 2, 4, 12, 14, 19, and 24 weeks after the first vaccination. ARl samples were kept frozen at -70°C until used. Serum antibody to botulinal type A toxin was first detected by the ELISA 4 weeks after the initial toxoid injection (2 weeks after the first booster) (Fig. 1 ). The antibody titer stayed level until the second booster vaccination at 12 weeks. The titer then continued to rise (from the initial optical density of 0.100 to 0.790) throughout the remaining study period. In contrast, no antibody was detected by the mouse neutralization assay until 19 weeks after the first booster vaccination (7 weeks after the second booster vaccination) (Fig. 1) . At this time, only undiluted serum was capable of neutralizing the toxin. The neutralizing antibody content of the serum, determined by the method of Hatheway et al. (3) , was equivalent to 0.125 IU/ml. This is the first report of a kinetics study of human antibody response to botulinal toxoids. The ELISA proved to be a sensitive and reproducible assay by which large numbers of serum samples could be screened. When coated plates were used, the assay was completed within 6 h. The ELISA was capable of detecting the antibody response to the toxoid as much as 15 weeks before demonstration of neutralizing antibody by the mouse assay (Fig. 1 ).
An indirect ELISA for detection of antibody response to botulinal toxins A and B in infant botulism was previously reported (5) . By coating the solid phase with a specific antitoxin, instead of a partially purified toxoid (5), we have now improved the specificity of the assay in a doubleantibody ELISA. This convenient procedure is also more economical than an indirect assay, because the antitoxin withstands long-term storage and because only minute amounts are needed for coating.
